دورية أكاديمية
Real-world data on treatment outcomes in EGFR-mutant non-small-cell lung cancer patients receiving osimertinib in second or further lines
| العنوان: | Real-world data on treatment outcomes in EGFR-mutant non-small-cell lung cancer patients receiving osimertinib in second or further lines |
|---|---|
| المؤلفون: | Dal Maso A., Lorenzi M., Ferro A., Pilotto S., Cecere F., Follador A., Polo V., Del Conte A., Sartori G., Giavarra M., Scattolin D., Indraccolo S., Frega S., De Maglio G., Menis J., Bonanno L., Calabrese F., Guarneri V., Conte P., Pasello G. |
| المساهمون: | Dal Maso, A., Lorenzi, M., Ferro, A., Pilotto, S., Cecere, F., Follador, A., Polo, V., Del Conte, A., Sartori, G., Giavarra, M., Scattolin, D., Indraccolo, S., Frega, S., De Maglio, G., Menis, J., Bonanno, L., Calabrese, F., Guarneri, V., Conte, P., Pasello, G. |
| سنة النشر: | 2021 |
| المجموعة: | Università degli Studi di Udine: CINECA IRIS |
| مصطلحات موضوعية: | acquired resistance, epidermal growth factor receptor, non-small-cell lung cancer, T790M mutation, tyrosine kinase inhibitors |
| الوصف: | Aims: This study describes real-world outcomes of pretreated EGFR T790M-positive (T790M+) advanced non-small-cell lung cancer patients progressing after first- or second-generation tyrosine kinase inhibitors and receiving osimertinib, compared with T790M-negative (T790M-) patients. We have also described progression patterns and treatment sequences. Patients & methods: This is a retrospective multicenter Italian observational study including consecutive Caucasian patients referred between 2014 and 2018. Results: 167 patients were included. Median progression-free survival was 9.8 months (95% CI: 8.3-13.3) for T790M+ and 6.0 months (95% CI: 4.9-7.2) for T790M- patients, respectively. Median overall survival was 20.7 months (95% CI: 18.9-28.4) for T790M+ and 10.6 months (95% CI: 8.6-23.6) for T790M- patients, respectively. The T790M mutation correlated with absence of new sites of disease. After progression, most T790M+ patients continued osimertinib, whereas most T790M- patients received a different treatment line. Conclusion: Better outcomes were shown in patients receiving osimertinib. A more limited progression pattern for T790M+ was suggested. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| العلاقة: | info:eu-repo/semantics/altIdentifier/wos/WOS:000650051900001; volume:17; issue:19; firstpage:2513; lastpage:2527; numberofpages:15; journal:FUTURE ONCOLOGY; http://hdl.handle.net/11390/1208490Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85107904377 |
| DOI: | 10.2217/fon-2021-0356 |
| الإتاحة: | https://doi.org/10.2217/fon-2021-0356Test http://hdl.handle.net/11390/1208490Test |
| حقوق: | info:eu-repo/semantics/openAccess |
| رقم الانضمام: | edsbas.EDCF4B59 |
| قاعدة البيانات: | BASE |
| DOI: | 10.2217/fon-2021-0356 |
|---|